Outcomes of stage IV patients with colorectal cancer treated in a single institution: What is the key to the long-term survival?

• Main Authors: Toshiki Mukai, Keisuke Uehara, Toshisada Aiba, Hayato Nakamura, Tomoki Ebata, Masato Nagino
• Format: Article
• Language: English
• Published: The Japan Society of Coloproctology 2018-01-01
• Series: Journal of the Anus, Rectum and Colon
• Subjects: stage IV; colorectal cancer; surgery; long-term survival; chemotherapy
• Online Access: https://www.jstage.jst.go.jp/article/jarc/2/1/2_2017-021/_pdf/-char/en

Objectives: The purpose of this study is to summarize our short- and long-term treatment results for stage IV colorectal cancer (CRC) and to clarify the factors predicting the favorable long-term survival. Methods: Between January 2008 and December 2015, 149 consecutive patients with stage IV CRC underwent initial treatment at Nagoya University Hospital. Their clinical and pathological characteristics, the treatment methods used, and the outcomes were retrospectively analyzed. Results: The median observation period was 23 months. All of the primary and metastatic lesions were technically resectable in 74 patients; however, the remaining 75 were judged as initially unresectable. R0/1 resection during the treatment course was achieved in 74 patients (50%). For the cohort as a whole, the 5-year overall survival (OS) rate was 35%. The 5-year OS rate in the R0/1 resection group was 57%, which was significantly better than that of the non-R0/1 resection group (6%, p < 0.001). In the R0/1 resection group, perioperative chemotherapy significantly improved the outcome (5-year OS; 62% vs. 0%, p = 0.03). In the non-R0/1 resection group, primary tumor resection was associated with a significantly higher favorable prognosis (3-year OS; 20.4% vs. 0%, p = 0.026). Moreover, the additional use of molecular targeted drugs significantly improved the survival. In multivariate analysis, the differentiated histologic type, R0/1 resection, and parallel use of molecular targeted drugs remained independent factors of a favorable outcome. Conclusions: The present study suggested that aggressive curative resection with perioperative chemotherapy might improve survival and that primary tumor resection might improve the outcome in the non-R0/1 group.